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Abstract. Induction of the urokinase type plasminogen 
activator receptor (uPAR) promotes cell adhesion 
through its interaction with vitronectin (VN) in the ex- 
tracellular matrix, and facilitates cell migration and in- 
vasion by localizing uPA to the cell surface. We provide 
evidence that this balance between cell adhesion and 
cell detachment is governed by PA inhibitor-1 (PAl-l). 
First, we demonstrate that uPAR and PAL1 bind to the 
same site in VN (i.e., the amino-terminal somatomedin 
B domain; SMB), and that PAI-1 competes with uPAR 
for binding to SMB. Domain swapping and mutagene- 
sis studies indicate that the uPAR-binding sequence is 
located within the central region of the SMB domain, a 
region previously shown to contain the PAl-l-binding 
motif. Second, we show that PAI-1 dissociates bound 
VN from uPAR and detaches U937 cells from their VN 
substratum. This PAL1 mediated release of cells from 
VN appears to occur independently of its ability to 
function as a protease inhibitor, and may help to ex- 
plain why high PAI-1 levels indicate a poor prognosis 
for many cancers. Finally, we show that uPA can rap- 
idly reverse this effect of PAI-1. Taken together, these 
results suggest a dynamic regulatory role for PAI-1 and 
uPA in uPAR-mediated cell adhesion and release. 
T 
UMOR invasion and metastasis depend upon the co- 
ordinated expression and temporal regulation of a 
series of proteolytic (Chen, 1992; Dano et al., 1985; 
Mignatti and Rifkin, 1993) and adhesive (Nesbit and Her- 
lyn, 1994)  events. Urokinase-type plasminogen activator 
(uPA) 1 is one of the proteases  frequently implicated in 
these processes  (Dano et al.,  1985; Mignatti and Rifkin, 
1993; Cohen et al., 1991; Vassalli et al., 1991). It is a serine 
protease that catalyzes the conversion of plasminogen into 
plasmin. Plasmin itself is a broadly acting trypsin-like en- 
zyme that not only degrades fibrin and a variety of extra- 
cellular matrix (ECM) proteins, but also may activate met- 
alloproteinases  (Mignatti  and  Rifkin,  1993; He  et  al., 
1989). Plasminogen (Plow et al., 1995) and uPA (Huarte et 
al., 1985; Roldan et al., 1990) bind to specific receptors, lo- 
calizing plasmin activity to the cell surface where it can be 
employed by migrating cells to degrade and/or modify tis- 
sue barriers during a variety of normal and pathologic pro- 
cesses (Mignatti and Rifkin, 1993). It is not surprising that 
many tumors  express  increased uPA  and  uPA receptor 
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(uPAR) (Del Vecchio et al.,  1993; Delbaldo et al.,  1995) 
since these molecules may provide the tumor cells with the 
necessary proteolytic activity for invasion (Heiss et al., 1995). 
It is difficult to reconcile this simple paradigm of sur- 
face-associated proteolytic activity and invasiveness, with 
two recent observations. First, uPA actually promotes the 
adhesion of U937 tumor cells to the adhesive glycoprotein 
vitronectin (VN) (Waltz et al., 1993; Waltz and Chapman, 
1994) rather than releasing them from their attachment to 
this ECM substratum. This activity depends on the binding 
of uPA, its amino-terminal fragment (ATF; residues 1-143), 
or its epidermal growth factor domain (EGF; residues 
1-48), to uPAR (Waltz and Chapman, 1994), and occurs in 
the presence of RGD peptides and/or EDTA (i.e., in an 
integrin-independent  manner)  (Waltz  and  Chapman, 
1994). uPA alters the conformation of uPAR (Ploug et al., 
1994),  increasing its affinity for VN  (Waltz et al., 1993). 
Second, many tumor cells express increased levels of PA 
inhibitor-1 (PAl-l) (Heiss et al., 1995; Sier et al., 1994) the 
primary endogenous inhibitor of uPA. Unexpectedly, this 
potent inhibitor of plasminogen activation is necessary for 
optimal invasiveness of cultured lung cancer cells (Liu et 
al.,  1995),  and an  increasing number  of studies demon- 
strate that high PAI-1 levels indicate a poor prognosis for 
survival of patients with breast (Grondahl-Hansen et al., 
1993), lung (Pedersen et al., 1994), gastric (Nekarda et al., 
1994), ovarian (Kuhn et al., 1994), and cervical (Kobayashi 
et al., 1994) cancer. These observations suggest that PAL1 
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nisms by which uPA promotes cell adhesion and PAI-1 fa- 
cilitates tumor cell invasion, remain to be delineated. 
Cells employ a variety of adhesion receptors to attach to 
the ECM, including proteoglycans (i.e., syndecans; Bern- 
field et al., 1993), integrins (Hynes and Lander, 1992),  and 
uPAR. Under most circumstances, the integrins appear to 
be the  more  important  of the  ECM  adhesion  receptors 
(Gumbiner,  1996).  They consist of a  large family of het- 
erodimeric  transmembrane proteins  composed of differ- 
ent combinations of e~ and 13 subunits which largely deter- 
mine their ligand specificity (Hynes and Lander, 1992).  In 
this context, the  exact role and biological significance of 
uPAR, a glycosylphosphatidylinositol (GPI)-anchored mem- 
brane protein (Behrendt et al., 1995; PIoug et aI., 1991),  in 
controlling cell adhesion remain to be determined. This al- 
ternative  adhesion  pathway  may  assume  importance  in 
some pathological situations. For example, recent studies 
show that the expression of various integrins is downregu- 
lated  in  many tumor cells  (Howlett  et  al.,  1995;  Haupt- 
mann et al., 1995;  Roussel et al.,  1994;  Boukerche et al., 
1994), and tumor cells frequently fail to deposit a fibronectin 
matrix around themselves (Rouslahti, 1994).  The fact that 
the uPAR system may be upregulated in migrating tumor 
cells (Behrendt et al., 1995; Gladson et al., 1995; Sier et al., 
1994;  Mignatti and Rifkin,  1993)  suggests that these cells 
may use this alternative adhesion pathway as a response to 
the disturbed expression of normal cell adhesion proteins. 
The above observations indicate  that the plasminogen 
activating  system  may  provide  both  surface-associated 
protease  activity  and  a  novel  adhesion  mechanism  for 
cells. However, in spite of the critical importance of uPAR 
in controlling these processes, the nature of the molecular 
"switch" that determines which response will dominate re- 
mains to be defined. The possibility that PAL1 itself is in- 
volved in these processes is suggested by the observations 
that this inhibitor binds to both uPA and VN but does so 
by quite distinct mechanisms. For example, PAI-1 binds to 
and inhibits uPA, but is inactivated in the process (Kruithof, 
1988; Loskutoff, 1991; Van Meijer and Pannekoek, 1995). 
Although PAI-1 also binds to VN with high affinity, it re- 
tains its activity and is,  in fact, stabilized by this interac- 
tion.  PAI-1 complexed with VN can still  bind to and in- 
hibit uPA (Knudsen et al., 1987) and tissue-type PA (tPA) 
(Declerck et al.,  1988;  Mimuro and Loskutoff, 1989).  In- 
terestingly, the  resulting PA/PAI-1  complexes have little 
affinity for VN, and are rapidly released from it. 
In this report we demonstrate that the binding site for 
uPAR  on  VN  is  contained  within  residues  1-41  at  the 
amino terminus of the molecule, the somatomedin B (SMB) 
domain (Deng et al., 1995; Jenne and Stanley, 1985;  Van 
Meijer  and  Pannekoek,  1995).  The SMB  domain  is  also 
the high affinity binding site for active PAI-1 in VN (Seif- 
fert and Loskutoff, 1991a). We also show that PAL1 effec- 
tively competes with uPAR for VN binding, that the inter- 
action between PAI-1 and SMB prevents the adhesion of 
U937  cells to VN,  and that low concentrations  of PAI-1 
rapidly release  U937  cells from their attachment to VN. 
These observations are incorporated into a model in which 
PAI-1  is  suggested  to  play  a  central  regulatory  role  in 
uPAR  mediated  cell  adhesion  and  release.  This  model 
may explain why high PAI-1  levels correlate with a poor 
prognosis for many cancers. 
Materials and Methods 
Materials 
Recombinant  human PAI-1  was  purified  from  Escherichia  coil  strain 
JM105 transformed with the PAl-1  expression plasmid pMBLll  as de- 
scribed previously (Seiffert et al., 1994).  Latent PAI-1 was generated by 
incubating active recombinant PAI-1 for 24 h at 37°C (Deng et al., 1996). 
Human high molecular weight two-chain uPA was from CalBiochem (La 
Jolla, CA). VN was purified from human plasma by heparin affinity chro- 
matography in the presence of urea (Yatohgo et al., 1988), and iodinated 
to a specific activity of 8.9 x  107 cpm/l~g by using the IODO-GEN system 
(Pierce,  Rockford, 1L).  The expression and purification of recombinanl 
SMB  and  SMB  mutants have been  described  previously (Deng et  al., 
1996). The EGF-like domain of human uPA (residues 1-48) was expressed 
and purified from recombinant yeast as described (Stratton-Thomas et al., 
1995). Biotinylated uPAR was labeled according to Kaufman et al. (1993) 
using soluble recombinant  human uPAR expressed and  secreted  from 
baculovirus-infected Sf9 insect cells as described (Goodson et al., 1994). 
ATF (residues 1-143 of uPA) and unlabeled soluble recombinant human 
uPAR were the kind gifts of Dr. Jieyi Wang (Abbott Laboratories, Ab- 
bott Park, IL). The anti-VN mAbs (1244 and 153) were developed and pu- 
rified as described (Seiffert et al., 1994). GRGDSP peptide was from Pen- 
insula Laboratories (Belmont, CA). 
Binding Assays 
The binding of uPAR to immobilized VN  was investigated by using a 
uPAR microtiter plate assay. Briefly, microtiter wells were coated with 
VN by incubating them in 100 pA of a solution containing 1 I~g/ml of VN in 
PBS at 4°C overnight. The wells were washed and then blocked by incuba- 
tion with 5% casein in PBS for 1 h. Biotinylated uPAR (10 nM), uPA (10 
nM) or the EGF domain of uPA (10 nM), and various competitors were 
added  to  the wells and  the plate  was incubated  at  37°C for  1  h.  The 
amount of bound uPAR was determined by employing streptavidin-alka- 
line phosphatase (Zymed Labs., So. San Francisco, CA) and the ELISA 
amplification system (GIBCO BRL, Gaithersburg, MD). The change of 
color was determined at 495  nM, and the O.D.  reading from duplicate 
wells was corrected by subtracting values for the wells incubated in the ab- 
sence of biotinylated uPAR. 
The binding of iodinated VN to U937 cells was quantified as follows. 
U937 cells at 106 cells/ml were incubated for 16 h in RPMI 1640 (BioWhit- 
taker, Walkersville, MD)  containing 10%  FBS  (GIBCO  BRL),  human 
transforming growth factor 13 (TGF-131) (Sigma Chem. Co., St. Louis. MO; 
1 ng/ml) and  la,25-dihydroxy-vitamin D3 (CalBiochem; 50 nM) (Waltz 
and Chapman, 1994).  The cells were then washed twice with serum-free 
RPMI containing 0.02% BSA (Sigma) and resuspended at 5 x  10  ~ cells/ml 
in the same media. The cells (0.2 ml) were then incubated with iodinated 
VN at 4°C in the presence or absence of various competitors, and after 90 
min, aliquots (50 ~1) were removed, layered on 0.3 ml of 20% sucrose, and 
centrifuged for 3 min at 12,000 rpm. The amount of iodinated VN associ- 
ated with the cell pellet was determined in a ~/counter. Triplicate determi- 
nations were made for each condition, and data are expressed as mean -  S.D. 
Cell Adhesion Assay 
U937 cells previously activated by culturing them in the presence of hu- 
man TGF-131 and vitamin D3 (as above), were washed twice, resuspended 
in serum-free media containing 0.02% BSA, and plated at 2.5  x  105 cells/ 
well in 96-well tissue culture plates precoated with 100 txl VN (2 ~g/ml), 
and blocked with 5%  BSA. The cells were incubated in the VN-coated 
wells for 3 h at 37°C in 5% CO2, and then the plates were washed three 
times to remove nonadherent ceils. Each step of the washing procedure 
included gentle agitation for  1-2 min in fresh media using a  microtiter 
plate mixer. Triplicate wells were then photographed at both low (40x) 
and high (200x) magnification. 
Results 
Active PAI-I Inhibits the Binding of uPAR to VN 
Recent studies suggest that PAL1 inhibits the adhesion of 
U937 cells to VN by binding to uPA and promoting the re- 
moval of both uPA and uPAR from the cell surface (Waltz 
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affinity (Deng et al., 1995; Salonen et al., 1989; Seiffert and 
Loskutoff, 1991b; Van Meijer and Pannekoek, 1995),  rais- 
ing the possibility that it may inhibit cell adhesion through 
its interaction with VN rather than through its interaction 
with uPA. A  series of experiments was performed to dis- 
tinguish between these possibilities. Fig. 1 shows that puri- 
fied recombinant PAI-1 does indeed inhibit the binding of 
VN to U937 cells, that it does so in a dose-dependent man- 
ner, and that 20 nM of active PAI-1 completely inhibited 
this  interaction.  Interestingly,  preincubation  of the  cells 
with PAI-1 to presaturate the uPA did not inhibit the sub- 
sequent  binding  of  iodinated  VN  to  the  cells  (Fig.  1, 
shaded bar). In fact, essentially all of the VN-binding sites 
were still available after this treatment. In contrast, prein- 
cubation of VN with purified PAI-1 prevented it from sub- 
sequently binding to purified uPA/uPAR complexes (Fig. 
2, open triangle). Moreover, active PAI-1 directly inhibited 
the binding of purified uPAR to VN immobilized onto mi- 
crotiter wells,  with  an  IC50 of ~10  riM.  In these  experi- 
ments, the EGF domain of uPA  (i.e., residues  1-48) was 
employed instead of uPA itself. The EGF domain of uPA 
cannot  bind  to  PAl-l,  but  still  binds  to  uPAR  and  en- 
hances  its  interaction  with  VN  (Waltz  and  Chapman, 
1994).  Inactive latent PAl-l, which does not bind to uPA 
or VN (Declerck et al., 1988; Wiman et al., 1988; Mimuro 
and Loskutoff, 1989),  showed no inhibition  in this assay. 
The  demonstration  that  both  purified  VN  and  purified 
uPAR inhibit the interaction (Fig. 2), indicates that these 
molecules specifically interact in this assay system. In sep- 
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Figure  1.  PAI-1  inhibits the binding of VN to U937 cells. U937 
cells were stimulated overnight with TGF-131/vitamin D3, washed 
extensively, and then incubated on ice for 90 min in the presence 
of  125I-labeled  VN  and  increasing  amounts  of  purified  PAI-1 
(open  bars). The  cells were  then centrifuged  through 20%  su- 
crose, and cell-associated VN was determined in a  ~/counter. In 
one experiment, the cells were preincubated with PAI-1 (20 nM) 
for 30 min, washed, and then the 125I-labeled VN was added for 
90 min (shaded bar). The latter data were not adjusted for cell 
loss due to the extra washing step. In these experiments, 100% of 
bound VN represented 5,900 cpm. 
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Figure 2.  PAI-1 inhibits  uPAR  binding  to VN.  Biotin-labeled 
uPAR (10 nM) and the EGF domain of uPA (10 nM) were added 
to VN-coated microtiter wells in the presence of increasing con- 
centrations of various competitors. The amount of bound uPAR 
was then determined by the uPAR microtiter plate assay  (see 
Materials  and Methods).  Competitors used in the assay include 
active PAI-1 (0), VN (O), uPAR (11), and latent PAI-1 ([]). In one 
experiment, the VN-coated wells were preincubated with PAL1 
(200 nM) for 1 h, the wells were washed, and then biotin-labeled 
uPAR and the EGF domain of uPA were added as above (A). 
arate experiments we demonstrated that  125I-labeled  VN 
binds  to  both  uPA/uPAR  and  uPA/uPAR/PAI-1  com- 
plexes immobilized on microtiter wells (data not shown). 
Taken together, these results indicate that PAI-1 inhibits 
the binding of uPAR to VN by a mechanism that depends 
upon its interaction with VN, and not with uPA. 
The Balance between uPA and PAI-1 Governs the 
uPAR/VN Interaction and Cell Adhesion 
The kD for the VN/PAI-1 interaction is ~0.3 nM (Seiffert 
and Loskutoff, 1991b), while the VN/uPAR interaction is 
10 nM (Waltz and Chapman, 1994).  The 30-fold higher af- 
finity of PAI-1 over uPAR for VN suggests that the inhibi- 
tor may be able to detach cells from their VN substratum. 
Cell adhesion assays were performed in order to test this 
hypothesis  (Fig.  3).  U937  cells  were  incubated  in  VN- 
coated wells in serum-free media for 3 h, and then PAI-1 
(40 nM) was added.  After another 1 h  of incubation, the 
wells  were  washed  three  times  to  remove  nonadherent 
cells, and then photographed. Fig. 3 shows that the pres- 
ence of excess PAI-1 caused the vast majority of cells to 
become nonadherent  and  to be released  from their  VN 
substratum. This effect occurs in a PAI-1 dose-dependent 
manner  (data  not shown),  in  agreement with  the  results 
shown  in  Fig.  1.  PAI-1  also  caused  the  release  of non- 
treated or PMA-treated U937 cells from VN. Incubation 
of these cells in media containing 0.5 mM GRGDSP pep- 
tide or 10 mM EDTA did not release the cells from VN 
(not shown). 
It is well established that PAI-1 inhibits uPA (Vassalli et 
al., 1991;  Van Meijer and Pannekoek,  1995)  and that the 
PAI-1  in  the  resulting  uPA/PAI-1  complexes no  longer 
Deng et al. uPAR-mediated Cell  Adhesion  1565 Figure 3.  PAI-1 detaches U937 cells from VN coated wells. U937 cells were stimulated  with TGF-131/vitamin D3 overnight,  and then 
seeded onto VN-coated cell culture wells in triplicate  in serum-free media containing 0.02% BSA. 3 h later, media alone (left  panels), 
media containing PAL1 (middle  panels), or media containing PAI-1 and uPA (right  panels) was added. The final concentration  of PAI-1 
and uPA in the wells was 40 nM and 100 nM, respectively.  The wells were incubated for an additional  60 min and then agitated and 
washed three times to remove nonadherent cells as described  in Materials  and Methods.  Representative wells from each set were then 
photographed at low and high magnification (top panels and bottom panels). 
binds to VN (Knudsen et al., 1987). In fact, the addition of 
uPA or tPA to VN, specifically releases any PAI-1 previ- 
ously  bound  to  it.  Therefore,  similar  experiments  were 
performed to investigate the effect of uPA on cell adhe- 
sion and release. Fig. 3  (right panels)  graphically demon- 
strates that uPA prevents the PAl-l-mediated release of 
U937 cells from VN.  This effect is  uPA  dose-dependent 
(data not shown), and excess uPA (i.e., 2-5-fold) is able to 
completely prevent the cell release by PAI-1. Similar ex- 
cesses of uPA and tPA completely inhibit and/or reverse 
the binding of PAI-1 to VN (Knudsen et al., 1987; Mimuro 
and  Loskutoff,  1989).  Interestingly,  the  uPAR  binding 
fragment of uPA (i.e., ATF) did not prevent this PAI-1- 
mediated release of cells from VN (not shown). Although 
ATF  binds  to  uPAR  and  enhances  uPAR/VN  binding 
(Waltz and Chapman, t994), it cannot bind to PAL1 (Cu- 
bellis  et  al.,  1989).  In  separate  experiments,  U937  cells 
were allowed to bind to 125I-labeled  VN in the absence or 
presence of PAI-1 and/or uPA (Fig. 4 A). In these experi- 
ments, uPA (lane 2)  and ATF (lane 3) slightly increased 
the  binding  of 125I-labeled  VN  to  the  cells  (compare  to 
lane 1), while 2 nM PAI-1 inhibited it by ~50%  (lane 4). 
The  subsequent  addition  of uPA  reversed  this  effect of 
PAI-1 (compare lanes 4 and 6), but ATF did not (compare 
lanes 4 and 5). Fig. 4 B demonstrates that tPA can also re- 
verse the anti-adhesive effects of PAI-1. This observation 
is significant because tPA does not bind to uPAR (Roldan 
et  al.,  1990;  Vassalli  et  al.,  1991;  Behrendt  et  al.,  1995). 
Moreover, the PAI-1 in tPA/PAI-1 complexes, like that in 
uPA/PAI-1 complexes, no longer binds to VN (Declerck 
et al., 1988; Mimuro and Loskutoff, 1989). 
Evidence that uPAR/uPA Complexes Bind to the SMB 
Domain of VN 
The fact that PAI-1 binds to the SMB domain of VN (Seif- 
fert and Loskutoff, 1991a)  and simultaneously blocks VN 
binding to uPAR  (Fig.  2),  suggests that  uPAR  may also 
bind to the  SMB  domain. If this hypothesis is true,  then 
purified SMB itself should competitively inhibit VN bind- 
ing  to  uPAR.  To  test  this  possibility,  we  compared the 
ability of wild-type recombinant SMB  and  a  non-PAI-1 
binding mutant of SMB (i.e., SMBy2sA; Deng et al., 1996) 
to compete with VN for uPAR  binding in the  microtiter 
plate assay (Fig. 5 A). The recombinant SMBs employed 
in these experiments contain residues 1 through 41 of VN, 
and  therefore do not include  the  RGD sequence  (Jenne 
and Stanley, 1985).  As shown in Fig. 5 A, active wild-type 
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Figure 4.  Evidence that it is the balance between uPA and PAl-1 
that governs the binding of uPAR to VN. (A) ~25I-labeled VN was 
incubated  with U937 cells for 90 min on ice as  in Fig.  1 in the 
presence of serum-free media containing 0.02% BSA alone (lane 
I), or supplemented with 10 nM uPA (lane 2), 10 nM ATF (lane 
3), 2 nM PAl-1 (lane 4), 2 nM PAI-1 and 100 nM ATF (lane 5), 
and 2nM PAI-1 and 10 nM uPA (lane 6). (B) lzSI-labeled VN was 
incubated with U937 cells in media alone (lane 1), or media con- 
taining 2 nM PAId (lane 2), 2 nM PAI-1 and 10 nM tPA (lane 3), 
or 2 nM PAI-I and 100 nM tPA (lane 4). 
SMB inhibited the binding of uPAR to VN, but the inac- 
tive  SMB  mutant  did  not.  We  previously  showed  that 
monoclonal  antibody  (mAb)  153  blocks  the  binding  of 
PAI-1  to  VN  (Seiffert  et  al.,  1994)  and  this  mAb  also 
blocked  the  binding  of VN  to  uPA/uPAR/PAI-1  com- 
plexes immobilized on plastic surfaces (Fig. 5 B). In con- 
trast, a second anti-VN mAb which did not inhibit PAI-1 
binding (i.e., mAb 1244; Seiffert et al., 1994), had no effect 
on this interaction.  These results indicate that the uPAR 
binding site in VN, like the high affinity PAI-1 binding site 
(Seiffert and Loskutoff, 1991a), is located in the SMB do- 
main. 
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Figure 5.  Evidence that uPAR binds to the SMB domain of VN. 
(A) Increasing concentrations of recombinant SMB (0) or of re- 
combinant  SMBy28A  (O)  were  added  to  VN-coated  microtiter 
wells in the presence  of uPA  and  biotinylated  uPAR,  and  the 
amount of bound uPAR was determined as in Fig. 2. (B) Equal 
concentrations of uPAR, 2 chain uPA, and PAI-1  (40 nM each) 
were mixed together and  coated onto  the wells of a  microtiter 
plate  by  incubation  at  4°C overnight.  The  wells were  blocked, 
washed,  and  125I-labeled  VN was  added  in  the presence  of in- 
creasing concentrations of an mAb specific for the SMB domain 
(i.e., mAb153; @), or an mAb whose epitope is located outside of 
this domain in the connector region of VN (i.e., mAb1244;  O). 
The  amount  of bound  VN  was  determined  in  a  3,  counter.  In 
these experiments, 100% binding corresponds to 7,200 cpm. 
uPAR on U937 Cells Also Binds to the SMB 
Domain of VN 
Experiments were performed to  test  the  possibility that 
the binding of VN to U937 cells also occurs through the 
SMB domain. Fig. 6 demonstrates that purified recombi- 
nant SMB decreases the binding of VN to U937 cells in a 
dose-dependent  manner,  while  the  inactive  Y28A  SMB 
mutant  had  no  effect.  Moreover,  inhibitory  mAb  153 
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Figure 6.  Evidence that uPAR on U937 cells binds to the SMB 
domain of VN. i25I-labeled VN was incubated with U937 cells for 
90 min at 4°C in the presence of serum-free media alone (lane 1), 
or media containing 2 t~M SMB (lane 2), 8 IxM SMB (lane 3), 3 txM 
SMB mutant Y28A (lane 4), 10 ixg/ml of mAb 153 (lane 5), or 10 
ixg/ml of mAb 1244 (lane 6). In all instances, the amount of cell- 
associated, 12SI-labeled VN was determined as in Fig. 1. 
blocked the binding of VN to U937 cells, but inactive mAb 
1244 did not. Thus, the interaction between VN and U937 
cells, like the interaction between VN and purified uPAR, 
is mediated by the binding of SMB to uPAR. 
Identification of Critical Residues in the SMB Domain 
for uPAR Binding 
Domain  swapping  and  mutagenesis  studies  were  per- 
formed  to more precisely identify  the  uPAR  binding  se- 
quence within the SMB domain. The SMB domain of VN 
is a cysteine-rich peptide (Fig. 7 A, top), and we previously 
showed that all eight cysteines are critical for maintaining 
the functional (i.e., PAI-1 binding) tertiary structure of the 
peptide  (Deng et al.,  1996).  These cysteines  appear to be 
organized into disulfide bonds, and substitution of any one 
of them with alanine resulted  in the formation of inactive 
peptides that no longer bind to PAL1  (Deng et al., 1996). 
Based  on  these  observations,  mutagenesis  experiments 
were performed under conditions  that did not change the 
cysteines. We initially tested the hybrid molecules created 
to define  the  PAI-1 binding  region in SMB  (Deng et al., 
1996),  and  demonstrated  that  the  uPAR  binding  motif, 
like the PAI-1 binding motif (Deng et al., 1996), is located 
in  the  central  region  of the  molecule  (data  not  shown). 
This  region  is  indicated  by the  overline  in  the  sequence 
shown in Fig. 7. We then converted the charged amino ac- 
ids in this region into alanines and tested the resulting pep- 
tides for uPAR binding activity in an assay similar to that 
used in Fig. 2. When either of the negatively charged resi- 
dues, Asp22 or Glu23, were converted into alanine, the re- 
suiting peptides  no longer bound  uPAR.  However, when 
positively charged  residues  within  this  region  (i.e.,  Lysl7 
and Lys18) were changed into alanines,  the resulting mu- 
tant peptides still bound to uPAR (Fig. 7 A). 
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Figure 7.  Mutational analysis of the uPAR binding site in SMB. 
Alanine  scanning mutagenesis  was employed to determine  the 
role of charged residues (A) and polar/hydrophobic residues (B) 
within SMB for uPAR binding. The uPAR binding activity of the 
following mutants  was tested.  (A)  Wild-type SMB  (0);  D22A 
(O); E23A (11); K6A,RSA (rq); and K17A,K18A (&). The amino 
acid sequence of wild-type SMB is shown across the top of this 
figure. The PAL1 binding region is overlined and critical residues 
for uPAR binding are underlined. (B) Wild-type SMB (0); L24A 
(D); Y27A (11); Y28A (O); and Y35A (&). All assays were per- 
formed in the uPAR microtiter plate assay as described in Mate- 
rials and Methods. 
In addition  to the cysteines  and the negatively charged 
residues,  several polar and hydrophobic  amino acids also 
were shown to be important in PAI-1 binding (Deng et al., 
1996).  These  residues,  along with  a  number  of others  in 
the  central  region  of  SMB,  also  were  individually  con- 
verted  into  alanines  and  then  assayed for uPAR  binding 
(Fig. 7 B). Among these residues, Leu24, Tyr27, and Tyr28 
were found to be essential for uPAR binding. 
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Although the specificity of cell adhesion to components of 
the extracellular matrix is largely determined by the inte- 
grin composition of the individual cell (Gumbiner, 1996), 
integrin-independent cell adhesion may also be important. 
For example, malignantly transformed cells often lose the 
ability to express specific integrins (Boukerche et al., 1994; 
Roussel et al.,  1994;  Howlett et al.,  1995;  Hauptmann et 
al.,  1995)  and to assemble fibronectin around themselves 
(Rouslahti, 1994).  Although such cells are frequently non- 
adhesive,  they  may  become  adhesive  under  certain  cir- 
cumstances (i.e., by using alternative adhesion molecules). 
The adhesive properties of U937 lymphoma cells illustrate 
this behavior. Although these cells do not normally adhere 
to ECM, Chapman and his collaborators showed that they 
could be induced to adhere to VN by treating them with 
TGF-131  and Vitamin D3 (Waltz et al., 1993), treatments 
subsequently shown to upregulate uPAR, uPA, and PAI-1 
(Waltz et al., 1993).  In a series of intriguing papers, these 
authors  demonstrated that this adhesion  occurred in the 
presence of EDTA (Waltz and Chapman, 1994), eliminat- 
ing the contribution of known integrins since integrins re- 
quire divalent cations for activity (Gumbiner, 1996; Hynes 
and Lander, 1992).  Adhesion required uPA and was medi- 
ated through  uPAR  (Wei et al.,  1994),  a  molecule origi- 
nally implicated in the localization of uPA to the surface 
of invading cells (Roldan et al., 1990; Behrendt et al., 1995; 
Estreicher et al., 1990).  The conclusion that uPAR plays a 
central role in this process is further supported by the ob- 
servation that nonadherent  293 cells became adherent to 
VN when transfected with uPAR cDNA (Wei et al., 1994). 
Finally, antibodies to PAI-1 appeared to promote the ad- 
hesion of U937 cells to VN, leading to the suggestion that 
PAI-1 itself would inhibit cell adhesion by binding to uPA 
on cells and inducing the internalization of the uPA/uPAR 
complex (Waltz et al., 1993; Cubellis et al., 1990).  The ob- 
servations in this report demonstrate directly that PAI-1 
inhibits uPAR mediated cell adhesion. However, in these 
studies, this effect of PAI-1 appears to be due largely to its 
interaction with VN and not with uPA. 
First,  we  directly  demonstrate  that  purified,  recombi- 
nant PAI-1 inhibits the binding of 125I-labeled VN to U937 
cells (Fig. 1), and that active but not latent PAI-1 inhibits 
the  binding  of purified  uPAR  to  purified  VN  (Fig.  2). 
Since these latter experiments were performed using puri- 
fied components (i.e., in the absence of cells), this effect of 
PAI-1  could  not  depend  upon  cell-mediated internaliza- 
tion  and  degradation.  In  this  regard,  preincubation  of 
U937 cells with PAI-1 did not reduce their ability to subse- 
quently bind to VN (Fig. 1), but preincubation of VN with 
PAl-1 blocked its ability to bind to purified uPAR (Fig. 2). 
These results suggest that PAI-1 inhibits cell adhesion in 
these  assays by interacting  with  VN  and  not with  uPA/ 
uPAR  complexes  on  the  cell  surface.  The  experiments 
shown in Fig. 1 were conducted under conditions of mini- 
mal internalization  (i.e., at 4°C). Thus, PAI-1 completely 
blocked the binding of cells to VN in the absence of uPAR 
mediated internalization.  PAI-1 also blocked, and in fact 
reversed, the interaction between cells and VN when the 
experiments were performed at 37°C  (Fig.  3).  Although 
this result could be due in part to PAI-1 mediated uPAR 
internalization,  the  uPA reversal experiments again sug- 
gest that uPAR  is  not involved. First  of all, PAL1  com- 
plexed to uPA on the receptor is no longer active and thus 
would  not be a  substrate  for the  added  uPA.  However, 
PAI-1 bound to VN can still bind to the excess added uPA 
and  the  resulting  uPA/PAI-1  complexes  would  be  re- 
leased.  These  latter  changes  would  be expected  to  pro- 
mote cell adhesion (Fig. 8). The fact that the inactive ATF 
fragment does not reverse the effect of PAI-1 at 4°C (Fig. 
4) or at 37°C (not shown) is consistent with this hypothesis 
since ATF binds to uPAR (Waltz and Chapman, 1994) but 
not to PAI-1 (Cubellis et al., 1989). 
Experiments were performed to identify the binding site 
in VN for uPA/uPAR. Since the high affinity binding site 
for active PAI-1  in VN is the SMB  domain (Seiffert and 
Loskutoff, 1991a), we initially examined this region of the 
molecule.  Fig.  5  shows  that  purified,  recombinant  SMB 
also blocked the binding of uPAR to VN (Fig. 5 A), and 
that  an  mAb  directed  to  the  SMB  domain  blocked  the 
binding  of  125I-labeled  VN  to  immobilized  uPA/uPAR 
(Fig. 5 B). Recombinant SMB and a mAb that blocked the 
binding of PAI-1 to SMB also blocked the binding of VN 
to activated U937 cells (Fig. 6). In control experiments, we 
showed that a mutant of SMB which does not bind to PAI-1 
(i.e., SMBvz8A),  and an mAb whose epitope was mapped 
outside  of the SMB  domain (i.e.,  1244),  had no effect in 
these  binding  experiments.  These  results  indicate  that 
both PAI-1  and uPAR bind to the SMB  domain of VN. 
Mutagenesis  studies  further demonstrate  that  these  sites 
are overlapping but distinct (Fig. 7). In this regard, the po- 
lar/hydrophobic  residues  shown  to  be  critical  for uPAR 
binding (Fig. 7) were also critical for PAI-1 binding (Deng 
et  al.,  1996).  However, when  we  directly  compared the 
critical residues  in  SMB  for PAI-l-binding  (Deng  et al., 
1996)  with those for uPAR-binding (Fig. 7), we noted one 
important  difference:  Glu23  was  necessary  for  uPAR 
binding but not for PAI-1 binding. This difference may in- 
dicate that uPAR requires more negatively charged resi- 
dues  in  SMB  for  binding  than  are  required  by  PAI-1. 
These results indicate that the sequence in SMB for uPAR 
binding is very similar to, but not identical with, the PAI-1 
binding sequence. 
Based  on  these  observations,  we  propose  that  PAI-1 
plays a central regulatory role in uPAR mediated cell ad- 
hesion (Fig. 8). The three key features of this model are 
that  uPA  stimulates  uPAR-dependent  cell  adhesion 
(Waltz et al., 1993), that uPAR binds to the SMB domain 
of VN (Figs. 5-7), and that PAI-1 also binds to SMB but 
with  considerably higher  affinity than  does  uPAR.  This 
difference  in  affinity  suggests  that  the  interactions  that 
govern cell adhesion and release will be regulated by the 
concentration of active PAI-1 available. According to this 
model (Fig. 8), cells will be nonadherent in the absence of 
either uPA or uPAR. Stimulation of cells in any way that 
causes the expression of both uPA and uPAR (e.g., with 
TGF[31 and Vitamin D3) will lead to the binding of uPA 
to cell-associated uPAR, an interaction that alters the con- 
formation of uPAR (Ploug et al.,  1994)  and promotes its 
binding  to  the  SMB  domain  of VN in  the  ECM.  These 
changes,  which  lead  to  the  formation  of stable  attach- 
ments, will occur only when uPAR is available and uPA is 
present  in  excess  over PAI-1.  Consistent  with  this  idea, 
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sion and release by PAI-1 and uPA. 
Western  blot analysis of SDS-extracts  of TGFI31/Vitamin 
D3  treated  adherent U937  cells  revealed  the presence of 
15 ng of uPA per 2.5 ×  105 cells and undetectable (i.e., less 
than  1  ng)  of PAI-1  (data  not shown).  If these  cells  are 
now  stimulated  or  otherwise  altered  to  produce  excess 
PAl-l,  the  inhibitor  should  compete  with  and  displace 
uPAR from its  association with  SMB,  releasing  the  cells 
from their VN substratum. This idea is supported by  the 
demonstration  that  low  concentrations  of PAL1  release 
U937 cells from their attachment to VN (Fig. 3). Interest- 
ingly, U937 cells attached to VN in this way cannot be re- 
leased  by  EDTA  or  an  RGD  peptide  (i.e.,  GRGDSP), 
suggesting  that integrins  are not involved in this process. 
Finally, this adhesive process is expected to be fully revers- 
ible, and excess uPA will again promote cell adhesion and 
invasion (Figs. 3 and 8). 
This  model  is  useful  because  it  provides  a  potential 
mechanism and testable hypothesis to account for the un- 
expected observation that PAI-1  is an independent marker 
for poor survival in many cancers (Pappot et al.,  1995).  It 
may also help us to understand the findings of Quax et al. 
(1991)  who  noted  that  metastasis  of  human  melanoma 
cells correlated with PAI-1  (Quax et al., 1991), and of Sier 
et al. (1994) who observed increased levels of PAI-1 in colo- 
rectal  cancer liver metastasis  (Sier  et  al.,  1994).  In these 
examples,  the  PAI-l-mediated  release  of cells  from VN 
would be expected  to promote the dissemination of these 
cells to distant tissue sites. The possibility that PAI-1  also 
influences the migration/invasion of these cells remains to 
be determined. In this regard, it should be noted that if the 
bound  uPA  is  in  its  proenzyme form,  PAI-1  will  not  be 
able to bind to and inactivate it (Andreasen et al.,  1986). 
The  released  cells  will be  fully  armed with pro-uPA  and 
therefore with the potential protease activity necessary to 
invade and remodel the ECM. 
This  demonstration that  PAI-1  regulates  cell  adhesion 
and release, and that it does so by binding to VN and not 
by inhibiting its natural substrate (uPA), sets it apart from 
other serine protease inhibitors  (serpins).  PAL1  also dif- 
fers  from  other  serpins  because  it  is  a  trace  protein  in 
plasma, it has a relatively short half-life (i.e., 10 min), and 
its biosynthesis is rapidly stimulated by a variety of inflam- 
matory mediators, growth factors, and hormones (for re- 
views  see  Loskutoff,  1991;  Van  Meijer  and  Pannekoek, 
1995). Moreover, PAId is an immediate-early gene (Pren- 
dergast and Cole, 1989) and has been shown to accumulate 
at  focal  points  of  adhesion  (Ciambrone  and  McKeown- 
Longo, 1992).  The short half-life and ability to be rapidly 
and dramatically upregulated, are the expected properties 
of molecules that have the potential to rapidly initiate  or 
terminate  biological  processes  (i.e.,  molecular  switches). 
Thus, by regulating the production rate and/or activity of 
PAl-l, cells may be able to control their adhesiveness and 
movement. 
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